Evidence map›Paper›PMID 38301184›Full record

ArticleJCO global oncology2024

Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines.

Fernando Valencia, Henry L Gómez, Silvia P Neciosup, Ronald Limón, María Del Carmen Torrico, Lena Morillas, Roberto Torres, Cesar Sánchez, Ingiborg Araya, Rodolfo Gómez and 9 more

Abstract read
In one paragraph

Article in JCO global oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Fernando ValenciaUniversidad Católica Santa Maria, Arequipa, Peru.ORCID 0000-0003-2475-0570
Henry L GómezOncosalud-AUNA, Lima, Peru.ORCID 0000-0002-4234-4448
Silvia P NeciosupNational Institute of Neoplastic Diseases, Lima, Peru.ORCID 0000-0002-2657-9853
Ronald LimónOncoBolivia-Centro especializado de cáncer, Clínica de las Américas-Departamento de Oncología, Santa Cruz, Bolivia.
María Del Carmen TorricoHospital Viedma, Cochabamba, Bolivia.
Lena MorillasCentro de Enfermedades Neoplásicas ONCOVIDA, La Paz, Bolivia.
Roberto TorresInstituto Nacional del Cáncer, Santiago, Chile.
Cesar SánchezCentro de Cáncer UC, Santiago, Chile.ORCID 0000-0001-7512-6474
Ingiborg ArayaInstituto Nacional del Cáncer, Santiago, Chile.
Rodolfo GómezInstituto de Cancerología de Las Américas de Medellín, Medellín, Colombia.ORCID 0000-0001-5597-5997
Ricardo BrugesInstituto de Cancerología de Bogotá, Bogotá, Colombia.
Carlos VargasUnidad de Cáncer, Clínica de Country, Bogotá, Colombia.
Tannia SoriaHospital SOLCA Quito, Quito, Ecuador.ORCID 0000-0001-5121-4023
René MuñozHospital de los Valles, Quito, Ecuador.
Mauricio RiofríoCentro Oncológico Quality of Care, Guayaquil, Ecuador.
Marco GálvezInstituto Regional de Enfermedades Neoplasicas del Norte, Trujillo, Peru.ORCID 0000-0002-0817-4174
Rossana RuizUniversidad Cientifica del Sur, Lima, Peru.ORCID 0000-0001-5199-6686
Pilar BenitesHospital Nacional Edgardo Rebagliati Martins, Lima, Perú.ORCID 0000-0001-8407-9710
Fatima CardosoBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.ORCID 0000-0002-6692-2249

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAs the fifth international consensus on advanced breast cancer (ABC5) established guidelines for the management of this disease, the aim of this article was to present the applicability of the consensus recommendations and to generate knowledge to improve access.

methodsSixty-one recommendation statements were selected and discussed by 15 breast cancer experts from Latin America (LA). After the discussion, the level of consensus was determined through a vote. In addition to this, the level of access to each of the recommendations presented, according to the country and health system, was exposed.

resultsLatin American experts had a high level of agreement with the ABC5 consensus recommendations (range, 83%-100%). Twelve of 61 statements are not available for all patients in LA. Among the limitations to access, the following ones are described: limited access to certain technologies (stereotactic body radiotherapy, positron emission tomography-computed tomography), the high costs of drugs that limits access to treatment with CDK4/6 inhibitors, pertuzumab, or poly(ADP-ribose) polymerase inhibitors, and the lack of molecular tests for access to therapeutic targets, as well as the difficult geography and cultural diversity of our continent.

conclusionDespite the great relevance of the recommendations of the ABC5 consensus guidelines, we highlight that we still need to improve access for all patients, regardless of the country or health system they are in, for which we call to action to policy makers and patient groups to improve clinical outcomes of patients with advanced breast cancer in our region.

Indexed as

Breast NeoplasmsConsensusFemaleHumansLatin America

Identifiers

PMID38301184
PMCPMC10846768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.